A 10 Week, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride (Aricept®) in the Treatment of the Cognitive Dysfunction Exhibited by Children with Down Syndrome – Ages 6-10. (E2020-A001-335/A2501061)

IRB# 2008-068

Principal Investigator: Hitendra Patel, MD

Synopsis:
An atrial septal defect (ASD) is an opening between the right and left upper chambers of the heart that may allow blood from the left heart chamber to cross the ASD, into the right side of the heart. Subjects on this study have already been scheduled for a procedure to implant the AMPLATZER® Septal Occluder to close the hole in the heart. The AMPLATZER® Septal Occluder is approved by the FDA to close atrial septal defects.

The purpose of this study is to gather more information about how effective the AMPLATZER® ASD Occluder is at closing the hole in patient’s hearts, as well as collecting information about the safety of the device.